• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

ocugen

Histogenics to merge with Ocugen

April 9, 2019 By Fink Densford

Ocugen, Histogenics

Histogenics (NSDQ:HSGX) said yesterday that it inked a definitive merger agreement with Ocugen through which both companies will combine into a single publicly-traded, clinical-stage biopharmaceutical company. The combined entity will operate under the Ocugen name, the companies said. As part of the deal, Ocugen’s shareholders will become the majority owners of Histogenics outstanding common stock upon […]

Filed Under: Business/Financial News, Featured, Mergers & Acquisitions, Wall Street Beat Tagged With: histogenics, ocugen

Ocugen wins orphan drug status for ocular gene therapy

February 14, 2019 By Sarah Faulkner

Ocugen logo - updated

The FDA has given Ocugen orphan drug status for a gene therapy designed to treat NR2E3 mutation-associated retinal degenerative disease. The Malvern, Penn.-based company’s OCU400 product includes an adeno-associated virum serotype 5 capsid that contains the gene for human nuclear hormone receptor NR2E3. In a mouse model of NR2E3 mutation, delivery of NR2E3 to retinal […]

Filed Under: Featured, Food & Drug Administration (FDA), Optical/Ophthalmic, Regulatory/Compliance Tagged With: ocugen

Ocugen kicks off dry eye disease trial for nanoemulsion eye drop

October 1, 2018 By Sarah Faulkner

Ocugen logo - updated

Ocugen said today that it launched a Phase III trial designed to evaluate its twice-daily 0.2% brimonidine tartrate eye drop in patients with dry eye disease. Ocugen plans to run two identical Phase III trials of OCU310, enrolling 240 participants per study. The company said it will assess safety and efficacy results after just 28 […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: ocugen

Ocugen launches Ph3 trial for eye disease nanoemulsion

July 2, 2018 By Sarah Faulkner

Ocugen logo

Ocugen said today that it launched the first of two pivotal Phase III trials for its OCU300 nanoemulsion designed to treat the symptoms of ocular graft versus host disease. The Malvern, Penn.-based company’s drug is a nanoemulsion formulation of brimonidine tartrate made using Ocugen’s OcuNanoE technology. Ocugen touted that it’s the first company to bring […]

Filed Under: Clinical Trials, Featured, Nanoparticles, Optical/Ophthalmic, Pharmaceuticals Tagged With: ocugen

Ocugen touts Ph2 data for dry eye disease combo therapy

March 20, 2018 By Sarah Faulkner

Ocugen logo

Ocugen touted positive data today from a Phase II proof-of-concept trial for its dry eye disease combination therapy, OCU310, which combines brimondine tartrate and loteprednol etabonate. The company’s randomized trial met its primary tolerability endpoint and showed meaningful improvements across endpoints related to the symptoms of dry eye disease, according to Ocugen. The Malvern, Pa.-based […]

Filed Under: Clinical Trials, Featured, Optical/Ophthalmic, Pharmaceuticals Tagged With: ocugen

How this biotech plans to go up against big pharma with its eye disease products

December 29, 2017 By Sarah Faulkner

Ocugen

Shankar Musunuri has spent time in both the pharmaceutical world and the biotech arena – after 15 years at Pfizer (NYSE:PFE), he went on to launch several biotech start-ups. As co-founder, chairman & chief executive of Ocugen, he is looking to bring eye disease products to the patients that big pharma’s drugs have left out. “There’s […]

Filed Under: Featured, Optical/Ophthalmic, Pharmaceuticals, Wall Street Beat Tagged With: Allergan, Massachusetts Eye & Ear Infirmary, ocugen, Pfizer Inc., Regeneron, Roche, Shire

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS